Probenecid (4-(dipropylsulfamoyl)benzoic acid): Inhibitor of Organic Anion Transport & Multidrug Resistance

Executive Summary: Probenecid is a well-characterized inhibitor of organic anion transporters and multidrug resistance-associated proteins (MRPs), effectively reversing drug resistance in MRP-overexpressing tumor cell lines (APExBIO). It inhibits pannexin-1 channels with an IC₅₀ of 150 μM, modulating ATP release and inflammatory signaling (source). In vivo, Probenecid demonstrates neuroprotection by reducing neuronal death and glial proliferation in cerebral ischemia/reperfusion injury models. It is chemically stable, insoluble in water, and typically supplied by APExBIO as a solid powder or DMSO solution. These properties enable its use in research on multidrug resistance, neuroinflammation, and transporter biology.

Biological Rationale

Multidrug resistance (MDR) in cancer arises from the overexpression of efflux transporters, notably members of the ATP-binding cassette (ABC) family such as MRPs. These proteins actively export chemotherapeutic drugs from tumor cells, decreasing intracellular drug accumulation and efficacy (see detailed review). Pannexin-1 channels play roles in ATP release and inflammation, with implications for neurodegeneration and ischemic injury. Targeting these proteins pharmacologically can restore drug sensitivity and limit inflammatory cascade propagation.

Mechanism of Action of Probenecid

Probenecid inhibits organic anion transporters and MRPs by blocking substrate binding and efflux activity. In tumor cells, this action increases the intracellular concentration of chemotherapeutic agents such as daunorubicin and vincristine, overcoming resistance mechanisms (Probenecid product page). Probenecid also inhibits pannexin-1 channels, reducing ATP-mediated signaling that drives inflammation. In models of cerebral ischemia/reperfusion injury, Probenecid prevents CA1 neuronal death by inhibiting the release of calpain-1 and cathepsin B, enzymes implicated in lysosomal and inflammatory damage (mechanistic insights).

Evidence & Benchmarks

• Probenecid reverses multidrug resistance in MRP-overexpressing HL60/AR and H69/AR tumor cell lines by resensitizing them to daunorubicin and vincristine in a concentration-dependent manner (APExBIO).
• Inhibition of pannexin-1 channels by Probenecid is observed at an IC₅₀ of 150 μM in cellular ATP release assays (Mechanistic Insights).
• In vivo, Probenecid reduces neuronal death, calpain-1 and cathepsin B release, and glial proliferation in rat models of cerebral ischemia/reperfusion injury (Mechanistic Article).
• Probenecid increases MRP protein levels in wild-type AML-2 cells without elevating MRP mRNA, indicating post-transcriptional regulation (Translational Leverage).
• Chemical properties: Molecular weight 285.36 g/mol; insoluble in water, soluble in ethanol and DMSO; stable at -20°C as a solid (APExBIO datasheet).

Applications, Limits & Misconceptions

Probenecid is utilized in research to:

• Reverse multidrug resistance in tumor cell lines by inhibiting MRP-mediated drug efflux.
• Investigate the role of pannexin-1 channels in ATP release and neuroinflammatory signaling.
• Study neuroprotective mechanisms in cerebral ischemia/reperfusion injury models.
• Probe the regulation of transporter protein expression and function.

This article extends the mechanistic frameworks discussed in "Probenecid: Mechanistic Insights into Multidrug Resistance" by providing detailed chemical and neuroprotective benchmarks. For a translational workflow perspective, see "Probenecid: Translational Leverage for Multidrug Resistance", which this article updates with new in vivo neuroprotection data.

Common Pitfalls or Misconceptions

• Probenecid is not effective against P-glycoprotein (ABCB1)–mediated drug resistance; its primary targets are MRPs.
• It does not increase MRP mRNA levels; observed effects on protein are post-transcriptional.
• Solubility in water is negligible; improper solvent use (e.g., aqueous buffers) leads to precipitation and loss of activity.
• Protective effects in ischemia/reperfusion models may not extrapolate to chronic neurodegeneration without further validation.
• Probenecid is supplied for research use only; not for human or veterinary therapeutic application.

Workflow Integration & Parameters

Probenecid (B2014) is available from APExBIO as a solid powder or a 10 mM DMSO solution. For transporter inhibition assays, typical working concentrations range from 50–250 μM, with efficacy validated in MRP-overexpressing cell lines. In pannexin-1 studies, 150 μM is a benchmark IC₅₀ value for channel inhibition. For in vivo neuroprotection models, dosing regimens should be referenced from peer-reviewed studies. Solutions should be freshly prepared and stored at -20°C; repeated freeze-thaw cycles are discouraged. For detailed protocols and advanced strategies, researchers may consult this mechanistic analysis, which this article complements by emphasizing real-world workflow parameters.

Conclusion & Outlook

Probenecid (4-(dipropylsulfamoyl)benzoic acid) is a validated inhibitor of organic anion transport and multidrug resistance, with additional utility as a pannexin-1 channel inhibitor and neuroprotective agent. Its dual action on transporters and inflammatory pathways provides a versatile platform for cancer, neuroscience, and immunometabolic research. Future directions include further mechanistic dissection of its regulatory effects and integration into translational workflows targeting multidrug resistance and neuroinflammation. Detailed product information and ordering are available directly from the APExBIO Probenecid product page.